Stocks and Investing
Stocks and Investing
Tue, October 15, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, October 14, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jayson Bedford Maintained (ABT) at Buy with Decreased Target to $90 on, Oct 14th, 2019
Jayson Bedford of Raymond James, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $93 to $90 on, Oct 14th, 2019.
Jayson has made no other calls on ABT in the last 4 months.
There are 2 other peers that have a rating on ABT. Out of the 2 peers that are also analyzing ABT, 0 agree with Jayson's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Jayson
- Joanne Wuensch of "BMO Capital" Maintained at Buy with Increased Target to $94 on, Thursday, July 18th, 2019
- David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $93 on, Tuesday, July 16th, 2019
Contributing Sources